SALARIUS PHARMACEUTICALS INC SLRX 深 滬
等待開盤 01-03 09:30:00 美东时间
0.652
+0.003
+0.49%
華盛通- 最 高0.67
- 今 開0.6488
- 成交量 52.96万股
- 最 低 0.6411
- 昨 收 0.6488
- 總市值 61.59万
- 52周最高 108.00
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 0.62
- 委 比 34.05%
- 總股本 94.46万
- 歷史最高 44445.00
- 量 比 3.95
- 振 幅 4.45%
- 歷史最低 0.6411
- 每 手 1
- 風險率 9.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Salarius Pharmaceuticals, Inc. has adjourned its 2025 Annual Meeting of Stockholders due to insufficient voter representation, with only 30% of shares voted. The meeting, originally held on December 19, 2025, will reconvene on December 31, 2025, at 10:00 a.m. Central Time, continuing virtually via live webcast. Shareholders of record as of October 24, 2025, are encouraged to vote promptly via the Internet at www.proxyvote.com, by phone at 1-800-6...
2025-12-19 16:12
Salarius Pharmaceuticals To Rebrand As Decoy Therapeutics Following Combination, Changes NASDAQ Ticker Symbol To DCOY
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker "DCOY" effective in early January 2026Company to focus on advancing lead antiviral programs,
2025-12-18 20:52
Salarius' Decoy Therapeutics Announces Collaboration To Conduct In Vitro Testing Of Decoy's Peptide Conjugate Fusion Inhibitors Across Several Influenza Strains Including H5N1 Avian Flu
Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting
2025-12-01 21:03
Salarius Pharma Cites Error On S&P CapIQ Platform; Reiterates Active Nasdaq Trading Under SLRX Ticker
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under
2025-11-20 03:47
3 Penny Stocks to Watch Now, 11/13/25
Leap Therapeutics, Amaze Holdings, and Salarius Pharmaceuticals are the 3...
2025-11-13 23:02
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Salarius Pharmaceuticals and Decoy Therapeutics have completed their strategic merger, with the combined company focused on advancing Decoy’s peptide conjugate therapeutics via its IMP3ACT platform. The merger provides the company with $14 million in pro forma cash after the merger and recent public offering. Decoy’s technology enables rapid drug design and manufacturing, targeting unmet medical needs in areas like respiratory infectious diseases...
2025-11-13 13:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 176.6% to $1.21...
2025-11-13 01:05
Shoulder Innovations (SI) Stock Rose 21% After-Hours: Here's Why
Shoulder Innovations shares jumped more than 21% in after-hours trading Tuesday after the company posted strong quarterly results and raised its 2025 revenue forecast.
2025-11-12 15:33
Salarius stock slides after pricing $7M offering
Salarius Pharmaceuticals (SLRX) has priced an offering to raise $7M in gross proceeds. The offering includes 2.5M common shares and pre-funded warrants to purchase 2.15M shares, each paired with Serie...
2025-11-12 01:02
